Clinical Trials on Primary Peritoneal Cancer

Total 98146 results

Richard van Hillegersberg

Terminated

Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study (CISCA)

Gastric Cancer | Peritoneal Carcinomatosis | HIPEC

Netherlands
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
The Christie NHS Foundation Trust

Unknown

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer

Sarcoma | Cervical Cancer | Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
M.D. Anderson Cancer Center

Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Fondazione Policlinico Universitario Agostino Gemelli...
Istituto Di Ricerche Farmacologiche Mario Negri; Foundation Medicine

Recruiting

Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25)

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Italy
Regina Elena Cancer Institute

Completed

Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)

Primary Peritoneal Neoplasm | Secondary Peritoneal Neoplasm

Italy
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Beth Israel Deaconess Medical Center

Completed

Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group

Completed

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Beth Israel Deaconess Medical Center
Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech, Inc.

Terminated

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Serous Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Daiichi Sankyo, Inc.

Completed

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Suspended

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Peritoneal Cancer

United States
Beth Israel Deaconess Medical Center

Completed

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Robert Morris
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Sheba Medical Center
Tel Aviv University

Withdrawn

Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies

Ovarian Cancer | Primary Peritoneal Cancer | Other Gynecological Cancers

Israel
Technische Universität Dresden
Deutsches Krebsforschungszentrum (DKFZ)

Recruiting

Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer (Hi-STEP1)

Gastric Cancer | Colon Cancer | Peritoneal Carcinomatosis

Germany
Gangnam Severance Hospital

Unknown

A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination

Peritoneal Carcinomatosis | Advanced Gastric Cancer

Korea, Republic of
Laval University
Ciusss de L'Est de l'Île de Montréal

Recruiting

Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms (DWI-HighRisk)

Colorectal Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Appendix Cancer | Appendix Neoplasm

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
Herbert Irving Comprehensive Cancer Center

Unknown

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Stanford University

Terminated

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Ovarian Germ Cell Tumor | Malignant Tumor of Peritoneum

United States
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Completed

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Charite University, Berlin, Germany
German Cancer Aid

Completed

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC)

Malignant Neoplasm of Stomach | Secondary Malignant Neoplasm of Peritoneum | Secondary Malignant Neoplasm of Other and Unspecified Sites

Germany
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Recruiting

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Peritoneal Carcinoma | Peritoneal Cancer | Desmoplastic Small Round Cell Tumor

United States
Fondazione Policlinico Universitario Agostino Gemelli...
Merck Sharp & Dohme LLC

Recruiting

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Italy
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University of California, San Diego

Terminated

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Fatigue | Anxiety | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC... and other conditions

United States
University of Pittsburgh
Genentech, Inc.; Novartis Pharmaceuticals

Completed

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Abramson Cancer Center of the University of Pennsylvania

Terminated

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma

United States
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Royal Surrey County Hospital NHS Foundation Trust
University of Surrey; Target Ovarian Cancer

Unknown

EDMONd - Elemental Diet in Bowel Obstruction (EDMONd)

Peritoneal Diseases | Ovarian Neoplasms | Peritoneal Neoplasms | Ovarian Cancer | Abdominal Neoplasm | Bowel Obstruction | Primary Peritoneal Carcinoma | Metastatic Ovarian Cancer | Ovarian Disease

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8

United States
University of Massachusetts, Worcester

Completed

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

Colorectal Cancer | Peritoneal Carcinomatosis | Appendix Cancer

United States
Prof. Aviram Nissan

Not yet recruiting

Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial

Metastatic Colorectal Cancer | Peritoneal Carcinomatosis | Colon Adenocarcinoma
Universitaire Ziekenhuizen KU Leuven

Recruiting

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed (HIPEC)

Pseudomyxoma Peritonei | Peritoneal Carcinomatosis | Peritoneal Mesothelioma

Belgium

Clinical Trials on Primary Peritoneal Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations